Download presentation
Presentation is loading. Please wait.
Published byJustina Fowler Modified over 9 years ago
1
Quezada et al. J. Exp. Med. Vol. 205 No.9 2125-2138 Presenters: Denise Rush Szymon Rus Harleen Saini
2
Mechanisms for Cancer Immunotherapy Stimulation of the immune system Inhibition of the immunological inhibitors Increased immunogenecity of tumor cells Stimulating bone marrow (G-CSF)
3
Improved Cancer Immunotherapy Understanding the effect of T reg cell depletion on anti-tumor immune responses Establishing synergy between T reg cell depletion and immunostimulation for effective tumor rejection
4
Targeting the inhibiting immunotherapy checkpoints ▪ Blocking CTLA4 ▪ CD4 + CD25 + T reg cell depletion T reg cells or regulatory T cells are CD4 + CD25 + Foxp3 + T reg cell depletion leading to enhanced T- cell response Studying the prophylactic and therapeutic effect of T reg cell depletion
5
CD25 + mediated T reg depletion ONTAK ▪ recombinant IL-2 fused to diphtheria toxin (DT) ▪ IL-2 internalized by IL2 receptor bearing cells ▪ Diphtheria toxin leading to apoptosis Foxp3 directed T reg cell depletion ▪ Foxp3-DTR transgenic mice
6
Anti-CD25 antibodies depleting CD25 + effector T cells Inefficient depletion of intra-tumoral CD25 + T reg cells Persistence of CD25 -/low Foxp3 + T cells Conversion of CD4 + Foxp3 - to CD4 + Foxp3 + cells
7
Gvax: GM-CSF-secreting cellular vaccine CTLA-4 inhibition Prophylactic versus therapeutic CD25 directed depletion of T reg cells
8
Mice were injected with anti-CD25 mAb 4 d before (prophylactic) or after (therapeutic) tumor establishment and then treated with Gvax/ αCTLA-4 on days 8, 11, and 14( Fig. 1 A ). Efficient depletion of CD4 + CD25 + T reg cells has occurred by 4 d after mAb injection ( Fig. 1 B ). Tumor growth was monitored over time for mice treated with Gvax/ αCTLA-4 (black squares), anti-CD25 d-4 and Gvax/ αCTLA-4 (blue triangles), and anti-CD25 d+4 plus Gvax/ αCTLA-4 (inverted red triangles). Although prophylactic CD25 depletion and Gvax/ αCTLA-4 synergized to reject established tumors, therapeutic CD25 depletion had no impact on tumor growth and rejection ( Fig. 1 C ).
9
Prophylactic or therapeutic CD25 depletion induced a significant reduction in the percentage of CD4 + Foxp3 + cells independently of Gvax or Gvax/ αCTLA-4 (Fig. 2 A ). Gvax and Gvax/ αCTLA-4 resulted in an increase in the absolute number of T reg cells over that of nonvaccinated mice (Fig. 2 B ). Analyses for expression of the proliferation marker KI-67: Gvax or Gvax/ αCTLA-4 induced a relatively modest increase in the percentage of KI-67 + CD4 + Foxp3 + cells. anti-CD25 resulted in a significant increase in the KI-67 + population. greatest increase was induced by the combination of anti-CD25 and Gvax or Gvax/ αCTLA-4 (Fig. 2 C ). Therapeutic intervention with Gvax or Gvax/ αCTLA-4 (after tumor implantation) induces accumulation of T reg cells, from surviving T reg cell populations that enter the cell cycle
10
Analysis of systemic anti-B16/BL6 melanoma responses by assessing T cell proliferation and cytokine production 14 d after tumor challenge. Gvax/αCTLA-4 treatment caused increased KI-67 expression in all compartments, with the biggest increase (more thanthreefold) in CD4 + Foxp3- T cells ( Fig. 3 A ). To address issues of specificity or functionality of the proliferating cells, melanoma TCR transgenic CD8 + (pmel) T cells were transferred into mice. Upon tumor challenge, an increase in KI-67 expression was observed in tumor-reactive pmel cells ( Fig. 3 B ). CD8 + and CD4 + T cells were purified and tested for IFN-γ and IL-2 production in response to the melanoma cell line. Gvax/αCTLA-4 caused a small but significant increase in IFN-γ production by both CD8 + and CD4 + T cells (Fig. 3, C and D ). Prophylactic CD25 depletion further increased IFN-γ secretion (Fig. 3, C and D ). Therapeutic CD25-depletion caused an additional significant increase (Fig. 3 C ). A similar trend was observed for IL-2. Prophylactic and therapeutic CD25 depletion does not result in elimination of effector T cells, but promotes strong systemic T cell responses against B16/BL6 melanoma.
11
Foxp3-DTR transgenic mice were used as tumor recipients( Fig. 4 A ) In contrast to CD25-directed depletion, this approach depletes CD25-/low Foxp3 + T cells upon DT injection ( Fig. 4 B ) Foxp3 + -directed depletion before challenge with B16/BL6 melanoma resulted in efficient tumor rejection, whereas late depletion failed to synergize with Gvax/αCTLA-4 ( Fig. 4 C ). Therapeutic Foxp3-directed T reg cell depletion failed to synergize with Gvax/αCTLA-4 in rejection of established tumors. Failure does not result from the effects of a pool of CD25 - /low Foxp3 + cells escaping CD25-directed depletion.
12
Intratumor responses 14 d after tumor challenge, and evaluation of expression of KI-67 by the effector T cell (CD4 + Foxp3- and CD8 + Tcells) and T reg cell (CD4 + Foxp3 +) compartments. More than 70% of CD4 + Foxp3 + T reg cells expressed KI-67 in untreated compartments. CD25 depletion drove mainly CD8 + T cells into the cell cycle, whereas Gvax/αCTLA-4 without CD25 depletion induced mainly CD4 + Foxp3- T cells to proliferate. Evidence for independent contributions of Gvax/αCTLA-4 and CD25 depletion to the expansion of the intratumor effector T cell compartment.
13
BL16/BL6 mice treated with anti- CD25 (-4 d or +4 d) plus Gvax/αCTLA-4 Untreated mice showed minimal T cell infiltration Prophylactic CD25 depletion resulted in T cell infiltration & increase of Effector/T-reg ratio Therapeutic CD25 depletion failed to increase number of effectors or switch ratio Similar results obtained after tumor-specific pmels transferred into mice before treatment
14
Only Prophylactic CD25 depletion resulted in co-expression of VCAM, ICAM and CD31 Activation of tumor vasculature not linked directly to T reg depletion Analyses of rejecting tumors reveals increased expression of ICAM & VCAM Expression correlates with infiltration & tumor rejection even in absence of T reg depletion
15
Without Gvax/αCTLA-4, prophylactic depletion resulted in small CD8+ infiltrate & increase in effector/regulator ratio Therapeutic depletion did not result in CD8+ infiltrate or change in ratio Changing the ratio of effectors/regulators must allow the combination of vaccination strategy to be effective
16
Irradiation induced a decrease in # of CD8+ and Foxp3+ cells DLI resulted in recovery of effector/regulator ratio Donor CD25 depletion increased effector function (IFN-γ production by CD8+ T cells) in response to B16/BL6 ICAM & VCAM only observed upon irradiation and T cell transfer Infiltrating T cells important factor to increase vasculature activation enhanced T cell infiltration and rejection
17
DLI from non-depletd mice resulted in delayed tumor growth & increased survival Maximal effects from DLI from CD25-depleted donors Correlated with enhanced activity & frequency seen with therapeutic depletion Tumor rejection not seen in mice lacking conditioning of the recipients, DLI or Gvax/αCTLA-4 vaccinations for recipients Recipient vaccination after DLI needed to further increase T cell numbers and reactivity against tumor
18
Therapeutic CD25-directed T reg depletion controls systemic accumulation of T regs & facilitates activation of systemic and intratumoral cells BUT few cells can access tumor due to abnormal vasculature and poor ICAM/VCAM expression Restricted infiltration results in low effector/T reg ratio and inability to induce tumor rejection Prophylactic T reg depletion allows infiltration of effectors into tumor that synergize with Gvax/αCTLA-4 to increase effector/T reg ratio and induce tumor rejection
19
Prophylactic vs. Therapeutic Model Therapeutic depletion allows tumor time to generate less permissive microenvironment for infiltration Prophylactic depletion allows T cells to infiltrate and contribute from within tumor to enhance vaccination effects Tumor reactive lymphocytes can be transferred into tumor- bearing hosts (after conditioning) for efficient activation of tumor vascularization, T cell infiltration and tumor rejection Applications for treating melanoma and other cancers
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.